1. Home
  2. AYTU vs BOF Comparison

AYTU vs BOF Comparison

Compare AYTU & BOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • BOF
  • Stock Information
  • Founded
  • AYTU N/A
  • BOF 2017
  • Country
  • AYTU United States
  • BOF United States
  • Employees
  • AYTU N/A
  • BOF N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • BOF Packaged Foods
  • Sector
  • AYTU Health Care
  • BOF Consumer Staples
  • Exchange
  • AYTU Nasdaq
  • BOF Nasdaq
  • Market Cap
  • AYTU 23.0M
  • BOF 27.6M
  • IPO Year
  • AYTU N/A
  • BOF 2023
  • Fundamental
  • Price
  • AYTU $2.10
  • BOF $3.23
  • Analyst Decision
  • AYTU Strong Buy
  • BOF
  • Analyst Count
  • AYTU 3
  • BOF 0
  • Target Price
  • AYTU $9.17
  • BOF N/A
  • AVG Volume (30 Days)
  • AYTU 62.6K
  • BOF 3.7M
  • Earning Date
  • AYTU 11-13-2025
  • BOF 11-12-2025
  • Dividend Yield
  • AYTU N/A
  • BOF N/A
  • EPS Growth
  • AYTU N/A
  • BOF N/A
  • EPS
  • AYTU N/A
  • BOF N/A
  • Revenue
  • AYTU $66,382,000.00
  • BOF $11,218,127.00
  • Revenue This Year
  • AYTU N/A
  • BOF N/A
  • Revenue Next Year
  • AYTU $29.12
  • BOF N/A
  • P/E Ratio
  • AYTU N/A
  • BOF N/A
  • Revenue Growth
  • AYTU 1.84
  • BOF 72.85
  • 52 Week Low
  • AYTU $0.95
  • BOF $1.53
  • 52 Week High
  • AYTU $2.82
  • BOF $3.37
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 41.10
  • BOF 62.76
  • Support Level
  • AYTU $2.01
  • BOF $2.79
  • Resistance Level
  • AYTU $2.18
  • BOF $3.30
  • Average True Range (ATR)
  • AYTU 0.13
  • BOF 0.30
  • MACD
  • AYTU -0.02
  • BOF 0.01
  • Stochastic Oscillator
  • AYTU 50.98
  • BOF 80.77

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

About BOF BranchOut Food Inc.

Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.

Share on Social Networks: